Renovaro's latest marketcap:
As of 09/30/2025, Renovaro's market capitalization has reached $29.24 M. According to our data, Renovaro is the 34573th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 29.24 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -59,231,206 |
| Shares Out | 230.93 M |
| EPS (ttm) | -0.38 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 11/13/2025 |
Renovaro's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 09/30/2025 | $29.24 M | -83.12% | 34573 |
| 12/31/2024 | $132.7 M | -37.23% | 21497 |
| 12/29/2023 | $211.4 M | 287.89% | 18487 |
| 12/30/2022 | $54.5 M | -85.68% | 26270 |
| 12/31/2021 | $380.7 M | 176.67% | 15027 |
| 12/31/2020 | $137.6 M | -40.77% | 18785 |
| 12/31/2019 | $232.3 M | -8.25% | 14045 |
| 12/31/2018 | $253.2 M | 12759 |
Company Profile
About Renovaro Inc.
Renovaro Inc. is a pre-clinical stage biotechnology company focused on developing innovative pharmaceutical and biological products for the treatment of cancer and HIV. Headquartered in Los Angeles, California, the company operates in the United States and the Netherlands.
Business Segments
Renovaro operates through two key segments:
- RENB: Specializes in genetically modified allogeneic dendritic cell therapeutic vaccines.
- RENC: Focuses on advanced AI-driven cancer detection technologies.
Key Developments
- RENB-DC11: A therapeutic vaccine targeting solid tumors, particularly pancreatic cancer.
- RENB-DC20: Designed for the treatment of breast cancer.
- AI Platform: Utilizes a multi-omics approach for early cancer detection and recurrence monitoring, identifying biomarkers in asymptomatic patients.
Corporate History
Formerly known as Renovaro Biosciences Inc., the company rebranded to Renovaro Inc. in February 2024.
Frequently Asked Questions
-
What is Renovaro's (RENB) current market cap?As of 09/30/2025, Renovaro (including the parent company, if applicable) has an estimated market capitalization of $29.24 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Renovaro (RENB) rank globally by market cap?Renovaro global market capitalization ranking is approximately 34573 as of 09/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.